A pharmaceutical company popular with retail investors.
2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Galt Pharmaceuticals in the last 30 days yet.
The 1 sources with the most insights about Galt Pharmaceuticals on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
The speaker is short the stock, as it was mentioned in a list of his current short positions.
Viewed as an attractive short target due to its popularity with retail investors, whom the speaker believes will eventually lose money, making it a stock they are 'excited to short it again'.
The speaker is short the stock, as it was mentioned in a list of his current short positions.
Viewed as an attractive short target due to its popularity with retail investors, whom the speaker believes will eventually lose money, making it a stock they are 'excited to short it again'.
Other assets that creators frequently mention in the same content as Galt Pharmaceuticals.
The most active sources covering Galt Pharmaceuticals (GALT) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Galt Pharmaceuticals (GALT) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Galt Pharmaceuticals (GALT) most frequently also discuss HUMA, MSFT, IFRX, NBIS, AMD. See the "Discussed alongside" section above for full asset pages.